area. The new research plan is organized around both short-term and long-term goals with the expectation that progress toward specific objectives can be achieved within a five to ten year time frame.
Introduction
Tuberous sclerosis complex (TSC) is a rare genetic dis order (w1:6000 live births) caused by inactivating muta tions in either TSC1 or TSC2.
1,2 The proteins encoded by TSC1 and TSC2, hamartin and tuberin, form a complex that negatively regulates the mechanistic target of rapamycin complex 1 (mTORC1).
3 mTORC1 is a kinase that regulates cell growth and anabolic processes in response to nutrient and growth factor stimulation. 3 Clinically, TSC individuals bearing TSC1 or TSC2 (TSC1/2) mutations develop nonma lignant tumors in multiple organs including the brain, eyes, heart, kidney, skin, and lungs, following a classic tumor suppressor paradigm. 1 However, for many individuals with TSC, the symptoms that most strongly impact quality of life are due to brain involvement, including seizures, intellec tual disability, and autism, by mechanisms that are not well understood. 4 The incidence and severity of TSC manifestations vary widely between individuals, and even between identical twins. 5 This phenotypic heterogeneity is likely due to dif ferences in mutations occurring in TSC1 vs TSC2 and other poorly defined factors. TSC is inherited in an autosomal dominant pattern with approximately two thirds of cases arising from de novo mutations. 1 In addition, many cases result from genetic mosaicism in which a somatic mutation in TSC1/2 occurs during early embryonic development. 6, 7 In somatic cells, a second-hit event causing complete loss of either TSC1/2 is typically required to cause unregulated mTORC1 activation and tumor development 1 ; heterogene ity arises from stochastic factors that affect the number and distribution of these second hits. Other potential contribu tors to the heterogeneity include cell-specific responses to the mutation, genetic modifying loci, and developmental and environmental factors, to name a few. This heteroge neity has posed major challenges in identifying effective treatments for TSC.
In 2001, Congress stated its support for the improved detection and treatment of TSC and directed the National Institutes of Health (NIH) to develop a long-range research plan for TSC (S.Con.Res.69, H.Con.Res.25). To assist in developing the first strategic plan for TSC research, the National Institute of Neurological Disorders and Stroke (NINDS), the Tuberous Sclerosis Alliance (TS Alliance), and the NIH Office of Rare Diseases Research convened an in ternational symposium in Chantilly, Virginia, in September 2002 leading to a comprehensive 5-to 10-year research plan for TSC that was published in 2003 (http://www.ninds. nih.gov/about_ninds/plans/tscler_research_plan.htm).
In 
Results

Progress in understanding and treating TSC
The workshop outcomes, described here, included reviewing the state of the TSC field and research progress since publication of the 2003 Research Plan (http://www. ninds.nih.gov/about_ninds/plans/tscler_research_plan.htm).
Elucidation of signaling pathways
Since 2003, tremendous progress has been made in un derstanding the functions of TSC1 and TSC2, and the mo lecular and cellular consequences of loss-of-function mutations in these genes. This progress was initiated by seminal findings in Drosophila followed by cell culture, and mouse genetic studies indicating that TSC1 and TSC2 inhibited cell and tissue growth. [8] [9] [10] [11] These studies led to the recognition that TSC1 (also referred to as hamartin), TSC2 (tuberin), and a third protein TBC1D7 form a protein com plex (the TSC complex) which acts as a sensor of cellular growth conditions and is an essential negative regulator of mTORC1 (reviewed in the studies 3, 12, 13 ). The TSC complex lies at the heart of a signaling network in which multiple different signaling pathways converge to regulate its func tion through direct phosphorylation of TSC2. In short, growth-promoting signals from growth factors, hormones, cytokines, nutrients, and cellular energy inhibit the TSC complex, leading to the activation of mTORC1. In contrast, poor growth conditions, such as growth factor or nutrient withdrawal or cellular stress, activate the TSC complex to turn off mTORC1. The TSC complex regulates mTORC1 by acting as a GTPase-activating protein for the Ras-related protein, Rheb, which in its GTP-bound form is an essential activator of mTORC1. Thus, in response to poor growth conditions, the TSC complex, through a GTPase-activating protein domain on TSC2, turns off mTORC1 signaling by stimulating the intrinsic GTPase activity of Rheb, leading to accumulation of GDP-bound Rheb, which cannot activate mTORC1. This regulation appears to occur primarily on the surface of the lysosome, where mTORC1 is independently recruited in response to amino acids.
14 Although our knowledge is yet incomplete, the TSC complex is recognized as one of the most highly integrated signaling nodes found in all cells, where its ability to perceive and relay cell intrinsic and extrinsic signals is key to the control of cell, tissue, and organismal homeostasis and growth. We have an even poorer understanding of TSC complex function in the brain; its diverse functions and those of mTORC1 likely underlie the diverse neurological manifestations of TSC.
Clinically, a seminal outcome from this body of work was the recognition that loss of TSC1/2 function causes mTORC1 to become constitutively active in TSC and insensitive to most growth-suppressive signals. This discovery led to preclinical and then clinical trials with allosteric mTOR in hibitors, such as rapamycin (sirolimus) and its analogs (often referred to as rapalogs), for the treatment of TSC manifestations (discussed in the following sections). More recently, novel mechanistic insights in TSC complex func tion and mTORC1 signaling are fueling new translational directions beyond the rapalogs. For example, novel anabolic functions induced by mTORC1 signaling have been discov ered, including de novo lipid and nucleotide synthesis, which combined with its established role in induction of protein synthesis, underlie its growth-promoting capacity (e.g., references [15] [16] [17] ). Disrupting the function of the TSC complex also affects feedback and crosstalk mechanisms within oncogenic signaling networks [18] [19] [20] and activates a variety of adaptive response pathways that enable TSC mutant cells to survive the metabolic stress that stems from uncontrolled mTORC1 signaling (e.g., [21] [22] [23] [24] ). New thera peutic interventions that selectively destroy cells with chronically activated mTORC1 signaling have been sug gested by such studies with the hope of eliminating tumors such as renal angiomyolipomas (AMLs) and subependymal giant cell astrocytomas (SEGAs) in TSC patients. Preclinical and clinical studies are underway to test such approaches.
Clinical progress in treating TSC
Remarkable progress in both clinical and translational research has resulted in Food and Drug Administrationapproved agents for the treatment of AML, SEGAs, and lymphangioleiomyomatosis (LAM). These efforts have created optimism about the future for additional targeted therapeutic strategies for the tumors that arise in TSC. However, in spite of these advances, there are still key gaps and questions in TSC pathogenesis, and a need to under stand better the underlying disease mechanisms, particu larly involving the neurological manifestations of TSC, to catalyze development of novel therapeutic approaches.
In the last 4 years, the first three randomized, placebocontrolled, double-blind studies in TSC and LAM were published and have changed clinical practice. For LAM, the Multicenter International Efficacy of Sirolimus (MILES) trial randomized 89 women with sporadic or TSC-associated LAM to receive either sirolimus (rapamycin) or placebo for 1 year, followed by 1 year of observation. 25 Sirolimus sta bilized and, by some measures, improved lung function, while lung function in the placebo arm continued to decline.
For SEGAs, the EXIST-1 trial randomized 117 individuals with TSC to either the rapalog everolimus or placebo 26 : 35% of patients in the everolimus group had at least 50% reduction in the volume of SEGAs vs none in the placebo group (P < 0.0001). For AML, the EXIST-2 trial randomized 118 individuals with AML to everolimus or placebo 27 : 42% of patients in the everolimus group had at least 50% reduction in the volume of AML vs 0% in the placebo group (P < 0.0001).
During this period of clinical progress, novel phenotypes and pathogenic mechanisms of TSC continue to be uncov ered. These include the increasing recognition of specific subtypes of renal cell carcinoma in children and adults with TSC, 28, 29 the discovery that 80% of women with TSC have evidence of cystic lung disease by age 40 years, 30 and the identification of "second hits" indicating that sun exposure is likely to be a major factor responsible for the develop ment of facial angiofibromas. 31 Progress in epilepsy associated with TSC TSC is one of the most common genetic diseases that manifest with epilepsy. Up to 90% of TSC patients develop seizures, most of them starting in infancy. Multiple types of seizures can occur, even within individual patients, and include focal (partial), multifocal, and generalized seizures that may evolve at different ages. Conventional seizure treatments are insufficient in at least one third of patients, causing a significant burden on patients and their fam ilies. 32, 33 The high prevalence of refractory seizures repre sents a significant unmet medical need. The mechanism by which TSC causes seizures continues to be uncertain. Tubers and the adjacent ("perituber") cortex have long been asso ciated with epilepsy. However, epileptiform discharges can occur in areas without tubers, and some TSC patients with epilepsy do not have tubers detectable by magnetic reso nance imaging (MRI). For very young children with TSC a common seizure type is infantile spasms. Indeed, any child presenting with infantile spasms should have a thorough evaluation for TSC. Vigabatrin is generally accepted as the first line of medical treatment for infantile spasms in chil dren with TSC although it is not yet clear why this drug is so effective in TSC. The lack of an authentic TSC mouse model with infantile spasms is a major limitation in this area of research.
A previous nonrandomized, open label trial suggested that vigabatrin treatment of TSC infants who developed abnormal electroencephalographs (EEGs) before epilepsy onset could prevent seizure development and improve intellectual outcome. 34 A recent prospective study has identified abnormal EEG as a predictive biomarker of impending clinical seizures in infants with TSC. 35 These studies raise the possibility of seizure prevention in TSC infants if a therapeutic window can be defined and pre ventive treatment can be given without toxicity. A ran domized clinical trial of early intervention with vigabatrin to prevent seizure development in TSC (EPISTOP) is currently ongoing in Europe, and an NINDSefunded trial to prevent epilepsy and improve neurocognitive outcomes in infants with TSC (PREVeNT) is being launched in the United States.
Understanding the neuropsychiatric manifestations of TSC Significant progress has also been made in understand ing the neuropsychiatric manifestations of TSC, with sig nificant impact on how they are managed. Nearly half of TSC individuals are affected with autism spectrum disorder, 36 with symptoms similar to those observed in "idiopathic" autism spectrum disorder. 37 Similarly, intellectual disability is a common problem in TSC. The intelligence/develop mental quotient is distributed in a bimodal fashion in TSC, with roughly half of scores fitting a normal distribution with a mean of 92, and half on a distribution with a mean of 42.6. 38 TSC can serve as an effective means to study early stages of autism and intellectual disability because patients can often be diagnosed with TSC in infancy or before birth due to the presence of cardiac rhabdomyomas. 39 There is also high frequency of anxiety, depression, attention deficit hyperactivity disorder and sleep problems in individuals with TSC. This constellation of neurodevelopmental issues in TSC has led to the definition of TSC-associated neuro psychiatric disorders (TAND) as a diagnostic entity. A TAND checklist has come into routine clinical use to assess these issues in TSC and was recently validated.
4,40
Development of animal models and launch of clinical studies in epilepsy and TAND Over a dozen different TSC mouse models have been developed that display combinations of epilepsy, hyperac tivity, anxiety, learning deficits, repetitive behaviors, and/or social interaction deficits. 41 These models provide insights into the cellular and circuit abnormalities underlying epi lepsy and TAND symptoms but have limitations in that they do not entirely replicate the human TSC phenotype (Table 1) . Rapalogs are universally effective in preventing or treating seizures and other neurocognitive phenotypes in TSC mouse models. These preclinical studies, and the effectiveness of these medications for AMLs and SEGAs have led to randomized placebo-controlled trials of rapalogs for epilepsy and neurocognition in TSC (NCT01713946, NCT01289912, NCT01730209, NCT01929642). The results of these trials are pending. However, it is becoming clear that the complexity of TSC neurodevelopmental manifestations poses a major challenge for selecting optimal outcome measures in neurocognitive trials. Thus, biomarker studies have been initiated (NCT01780441, NCT01767779) to (1) predict individual patient response to treatment, (2) select subpopulations of patients for clinical trials, and (3) serve as intermediate or surrogate markers of efficacy with the goal of accelerating progress in clinical trials.
Research opportunities and priorities moving forward
The workshop identified five high-priority areas that, if addressed over the next five to ten years, are anticipated to speed progress in our understanding and treatment of TSC. Summarized in the following sections are the key gaps, needs, and challenges recognized to hinder progress in each of these priority areas, along with spe cific sets of research recommendations for addressing the challenges.
Priority Area I: Understanding phenotypic heterogeneity in TSC
Although a Mendelian disorder, phenotypic heteroge neity is the rule in TSC and manifests as differences in the severity or even presence of symptoms between affected individuals, as well as differences in the severity of different phenotypes within the same individual. For example, one Understanding phenotypic heterogene ity in TSC is crucial for improving knowledge about under lying mechanisms and natural history and for developing optimal prognostic tools, biomarkers, and targeted treat ments for the disorder. Accordingly, the workshop identi fied two short-term and two long-term goals that would address the mechanisms and implications of this hetero geneity ( Table 2 ). The first short-term goal is the development of a bio bank/database to serve as a repository for biological sam ples (e.g., DNA, blood and other tissue samples) from individuals with TSC and associated genetic and clinical data for open dissemination among TSC investigators. The TS Alliance has taken a leadership role in the organization of this important resource, which will require continuing development and curation to maximize its impact for studies of phenotypic heterogeneity in TSC. A second and related short-term goal involves leveraging the power of new sequencing technologies (e.g., whole genome or whole-exome sequencing) for deeper genetic analysis of TSC families and expanding the capability of the genetic testing community for routine detection of mosaic muta tions and other detailed mutation assessments in TSC. Until recently, most genetic diagnostic laboratories had limited ability to identify mosaicism or rarer TSC mutations, which has hampered our full understanding of the genetic architecture of TSC and associated genotypeephenotype relationships. For example, mosaicism appears to be rela tively common in TSC, and it may be associated with a milder phenotype than nonmosaic TSC. 7, 59 Using these important resources (bio/databank and enhanced genetics analysis), the workshop identified two long-term research goals that respectively seek to tackle the genetic and environmental causes of phenotypic hetero geneity in TSC (Table 2 ). To address these goals, there is a need for comprehensive "omics" and systems-level computational approaches to decipher the complex and intertwined genetic and environmental underpinning of the heterogeneity, particularly by accessing a diversity of clinical samples (e.g., different cell and tissue types) from the biobank. DNA sequencing studies of TSC families, e.g., may identify genetic modifiers that influence the pheno type. In addition, detailed mechanistic studies in animal models are required, ideally conducted in parallel to clinical investigations, to yield insight into the underlying causes of heterogeneity. Such model systems enable in depth explo ration of the genetic and environmental causes of hetero geneity and their interactions, in a manner not possible in human studies.
Priority Area II: Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency
The TSC complex is a key signaling hub that is modulated through phosphorylation by numerous protein kinases in response to multiple types of extracellular stimuli 12 and that in turn negatively regulates the activity of mTORC1 as described previously. Downstream, mTORC1 regulates a diverse set of cellular functions including protein synthesis, mRNA and ribosome biogenesis, lipid and nucleotide syn thesis, mitochondrial metabolism, and autophagy, to name a few.
3,60 Cellular signaling networks are by their nature complicated computational entities, posing challenges for Short-term goals:
1. Establish a Bio/Data repository to promote sharing of information/resources and include:
• a central database for linking clinical/phenotypic information to sequence data and biospecimens • genetics/genomics data from TSC probands/families (e.g., DNA/RNA sequences) • a rich diversity of patient-derived cell lines, biospecimens, and tissues 2. Expand the use of next-generation sequencing technologies for deeper genetic analysis of TSC families, including routine genetic detection of mosaicism and rarer forms of TSC mutations
Long-term goals:
3. Use computational and "omics" approaches with resources from the Bio/Data repository to investigate the genetic causes for the heterogeneity between and within individuals including the role of:
• specific TSC1/2 patient mutations on the phenotype • mosaicism • genetic modifiers/secondary loci that contribute to the severity of the phenotype • epigenetics 4. Explore nongenetic contributions to phenotypic heterogeneity in TSC including the role of:
• environmental exposures, inflammation/infection, tumor microenvironment, endocrine and stress responses, sleep, dietary influences, etc.
• epilepsy on neurocognitive development development (age of patient) • unraveling their functions. By mechanisms that are poorly understood, the activities of diverse upstream regulators and downstream effectors of the TSC complex are influ enced by the many genetic and environmental sources of heterogeneity in TSC (Priority Area I), which collectively give rise to heterogeneity at the cellular, circuit, and network levels and consequently in the clinical manifesta tions of TSC. The workshop identified both short-term and long-term goals that would help basic scientists and clini cians to gain a deeper understanding of altered signaling pathways in TSC and their clinical consequences (Table 3) .
Of immediate benefit would be a better toolbox for TSC researchers including antibodies, constructs, pharmaco logical grade compounds, and novel reporters that, in conjunction with the resources from the bio/databank (Priority Area I), could be used to monitor and probe signaling pathways and cellular functions that are known to be regulated by the TSC complex and mTORC1. These tools should be openly disseminated in the form of an easily searchable database to enable easy access.
The workshop identified multiple long-term research goals that are imperative for unraveling the extraordinarily complex and dynamic nature of the TSC signaling network. These objectives include obtaining detailed structural knowledge of the large (w2 MDa) TSC protein complex 14 and quantitatively assessing the TSC signaling network using proteomics, phosphoproteomics, metabolomics, transcriptomics, and translatomics in combination with systems/computational analytic approaches. It will also be important to identify the key upstream signaling inputs and to decipher the role of mTORC1-independent path ways in TSC. Harnessing the computational power of bio informatics approaches will be critical to these endeavors, as well as studying a diversity of cell types and in both heterozygote and homozygote mutant TSC cells as high lighted below.
It is becoming increasingly clear that different cell types can exhibit different phenotypes in response to TSC1/2 deficiency and mTORC1 activation. For example, in response to TSC1/2 loss, basic cellular processes, such as autophagy, are differentially perturbed in neuronal vs non-neuronal cells. 22 ,61 Different neuronal cell types (e.g., hippocampal vs cerebellar Purkinje neurons) can also respond very differently to TSC1/2 loss, e.g., regarding perturbations in dendritic spine dynamics. 45, 57 Moreover, in contrast to tu mor formation in TSC, which requires second-hit events (discussed previously), a number of studies have docu mented the deleterious effects of single copy loss of TSC1/2 (haploinsufficiency) on synaptic connectivity and behavior in TSC mouse models. 55, 56, 62, 63 Further analysis and mech anistic understanding of this phenomenon is required and may help to explain multiple aspects of TAND. These cell type and regional differences in responding to TSC muta tions highlight the importance of investigating the impact of mutations in different spatial and temporal settings, in diverse cell types and at specific stages of development. A Short-term goal:
Develop a better toolbox for TSC researchers
• in addition to a clinical Bio/Data repository, establish a repository and database of available molecular tools/reagents (e.g., antibodies, tool compounds, reporters, constructs), cell lines and animal models to promote sharing and dissemination of information about these resources
Long-term goals:
2. Delineate TSC-dependent signaling networks quantitatively in both homozygous and heterozygous disease-relevant cells
• determine the 3-dimensional structure of the TSC protein complex and define the molecular basis of its interactions with Rheb and other proteins • employ unbiased "omics" (e.g., proteomics, phosphoproteomics, metabolomics, transcriptomics, translatomics) and systems/computational approaches to understand the cellular consequences of mutations in TSC1 and TSC2 • tease apart the role of mechanistic target of rapamycin complex 1 (mTORC1)edependent and mTORC1-independent pathways, and the role of mTORC2 in TSC • understand the upstream regulators of the TSC complex in different contexts 3. Develop a thorough understanding of cell-and tissue-specific manifestations of TSC deficiency; e.g., delineate:
• cell-specific differences in the consequences of TSC1/2 mutations; e.g., phenotypic differences in neuronal vs non-neuronal cells, in excitatory vs inhibitory neurons, and so forth • the role of homeostatic or compensatory/aggravating mechanisms (including interactions with other pathways) in modifying the impact of mutations within cells • developmental influences on the phenotype 4. Understand non-cell autonomous effects of TSC1/2 deficiency; e.g., understand:
• how TSC1/2 deficient cells impact the functioning of neighboring cells (e.g., wild-type cells in mosaicism) or modify circuit/network dynamics in the brain • the role of the microenvironment in LAM and TSC pathology: e.g., interactions with the tumor stroma and inflammatory cells; lung destruction and lymphangiogenesis in LAM; and angiogenesis in AML and skin lesions • the role of neuroneglial interactions in the TSC phenotype major gap, however, is the limited availability or difficulty in deriving cultures from some cells or tumors (e.g., TSCassociated SEGAs, AMLs, angiofibromas, LAM). 64, 65 Another long-term goal is to identify non-cell autono mous effects of TSC1/2 deficiency (both heterozygous and homozygous) in available cell models, animal models, and patient-derived cells and tissues (Table 3) ; i.e., how does dysregulation of the TSC signaling network in one type of cell impact the function of other cells in a tissue? Priority Area III: Improving TSC disease models
The workshop participants identified the need for both new cellular and animal models of TSC (Table 4) . A tech nology that may prove transformative for TSC research is the use of induced pluripotent stem cells. 66 This approach is based on the ability to reprogram somatic cells (e.g., skin fibroblasts or lymphocytes) obtained from patients with diseases such as TSC into stem cells. The technology for the generation of these lines is now fairly robust, but their utility and reproducibility in the analysis of human phe notypes is still under investigation. Importantly, the use of genomic engineering technologies such as TALEN (tran scription activator-like effector nucleases) and CRISPR (clustered regularly interspaced short palindromic repeats) enables the generation of paired isogenic control and TSC lines that harbor specific mutations, enhancing utility. The future availability and distribution of induced pluripotent stem cell lines from TSC patients curated with associated phenotype/genotype data and the validation of findings using multiple TSC patient cell lines will add a crucial dimension to boost translational research in TSC.
Numerous (>20) distinct TSC animal models (primarily mouse) have been generated since 2002, which capture various features of the human disease (Table 1 includes 14 models with neurological phenotypes). When interpreted within the scope of their limitations, these models provide valuable insight into underlying disease mechanisms. The current models use a variety of genetic techno logies, including conditional alleles that allow for cell typeespecific or regional deletion of Tsc1/2 and the concomitant dysregulation of the mTOR pathway or per mutations that capture the genetic mosaic nature of TSC. 59 Not surprisingly, given the genetic and phenotypic hetero geneity of the human disorder (not to mention the influence of evolution particularly on brain development), no single genetic model recapitulates precisely the full pathology seen in human TSC; collectively, however, the models can provide important insights into TSC disease biology. Two phenotypes that converge in nearly all the brain models (Table 1) are increased levels of phospho-S6 and increased cell growth, the molecular and cellular consequences of uncontrolled mTORC1 signaling. Most models also have an Short-term goals:
1. Use rigorous study design and transparent reporting to advance the most robust and reproducible preclinical concepts to clinical testing; e.g., for preclinical therapeutics development:
• ensure blinding, randomization, appropriate controls, power, and statistics • use human-relevant doses in animal models and incorporate pharmacokinetic (PK)/pharmacodynamics (PD) measures • consider both timing (in relation to symptom onset or treatment windows) and duration of treatment, corresponding as closely as possible to the clinical indication • identify robust and reproducible phenotypes (e.g., conserved across multiple TSC mouse models and/or background strains, or across species) to increase confidence that preclinical results will translate to humans • align clinical and preclinical studies, adopting "reverse translation" strategies when possible; e.g., clinical biomarkers or intermediate phenotypes identified from TSC patients (discussed below) that can be recapitulated in animal models • replicate promising preclinical treatment findings in more than one model and in independent laboratories 2. Establish a "Preclinical Trials Network" to accelerate translation to human studies • develop models with improved construct validity (e.g., mosaic models, patient-specific mutations)
• in addition to mouse models, diversify the "animal model toolbox" by developing rat and nonrodent mammalian models for preclinical studies • employ zebrafish/Drosophila models to facilitate the study of genetic modifiers in TSC 4. Develop a diverse set of cell-based models representing different cells, tissues, and organs affected by TSC
• consider cell of origin • human induced pluripotent stem cell (iPSC) lines with paired single/double hits and isogenic controls • patient-derived xenografts (PDX) • 3D organ culture and tissue-chip technologies epilepsy or seizure phenotype (induced or spontaneous), whether targeting gene deletion to astrocytes, neurons, or progenitor cells. Posing a challenge for studies of TAND, a more limited subset has aberrant behavioral features. Mul tiple non-brain TSC models have also been developed and used successfully for therapeutic testing (e.g., rapamycin for tumor elimination). However, there are no practical models yet that replicate human AML or LAM, highlighting the need to develop better tumor models of TSC. Hence, the work shop participants recognized the need to develop and disseminate a diverse "toolbox" of models to accelerate translational progress in TSC.
Given the many failures to translate findings from animal models to humans, [67] [68] [69] mouse model development is currently in a stage of reexamination and revitalization. For example, the field is recognizing the need to identify robust and reproducible phenotypes, particularly those that are conserved across multiple mouse models and strains or even across species, to increase confidence that preclinical results will translate to humans. 70, 71 In that light, many drug development programs are moving away from using complex, highly strain-dependent behaviors in rodent effi cacy assays (e.g., reversal of social impairments in mice), relying instead on more robust, evolutionarily conserved phenotypes that capture underlying biology or circuit function. 72 Reverse translational and iterative approaches, e.g., identifying clinical biomarkers or intermediate phe notypes in TSC patients (Priority Area IV) that can be reca pitulated in animal models, are also being explored to improve the informative value of both preclinical and clin ical markers used in translational research.
Furthermore, preclinical studies are often not rigorously designed or reproducible. Consequently, the NIH and leading scientific journals recognize the urgent need to submit pre clinical studies to the same standards of rigor (e.g., blinding, randomization) and transparency that are expected of hu man clinical trials 73, 74 ; also, see recent NIH guidelines: http://grants.nih.gov/reproducibility/index.htm. In addi tion, when testing the efficacy of pharmacologic in terventions in preclinical models, it is imperative to obtain pharmacokinetic (PK) end points in plasma and/or the tissue in which the drug target is expressed [75] [76] [77] and directly compare PK with pharmacodynamics (PD) end point(s). Finally, the most promising treatments should undergo replication, ideally in an independent laboratory and/or us ing another TSC model, before the advancement to late-stage translational or clinical testing. The lack of PK/PD relation ships, the absence of appropriate controls, and the lack of randomized, blinded, and sufficiently powered preclinical studies are likely to undermine translational success in TSC.
There is recognition of the financial and logistical chal lenges for academic laboratories to conduct PK/PD and replication studies, along with a need for additional re sources and partnerships. Funding agencies including the NIH, DOD TSCRP, and TS Alliance have a number of funding mechanisms that are specifically designed to support such studies (Supplemental Data: Appendix 4). Furthermore, a strong recommendation is to establish a preclinical TSC trials network that has an integrated mouse models consortium component. The network would serve as a centralized resource for existing and new genetic models and provide an in-depth description of the study design, methods, pharmacologic or other agents used, results (including PK/ PD and independent replication outcomes), and utility of the models for different preclinical applications. The TS Alliance has taken a leadership role and begun to organize a TSC Preclinical Trials Network to include investigators with expertise in TSC mouse models and the different organ sys tems affected by TSC along with industry experts to guide drug-discovery criteria. Table 4 lists specific strategies to achieve each of the goals in Priority Area III.
Priority Area IV: Developing clinical biomarkers for TSC Biomarkers, defined broadly as characteristics of the body that can be measured in relationship to disease, can facilitate advances in a myriad of aspects of clinical care and trials. Biomarkers can be powerful tools in a variety of do mains to (1) aid in disease screening and diagnosis (diag nostic biomarker), (2) provide prognostic information about the natural history of disease (prognostic), (3) predict in dividual treatment response and patient stratification for clinical trials (predictive), (4) yield insights into disease pathogenesis (pathogenic), and (5) serve as predictors of target engagement, PD measures, or efficacy for clinical trials (PD/response). Advances in biomarker development in TSC will provide synergy to all priority areas in TSC (Table 5 outlines specific strategies to achieve this goal).
There are numerous types of biomarkers currently used in TSC clinical practice. For example, imaging modalities (MRI, computed tomography or ultrasound) provide organspecific measures of tumor burden. Pulmonary function tests are used to measure the severity of LAM or disease progression. Serum vascular endothelial growth factor D, a lymphangiogenic growth factor, facilitates LAM diagnosis and has a potential role in prognosis estimation and pre diction of response to sirolimus. Biomarkers are particularly crucial for measuring neurological and psychiatric mani festations of TSC. The EEG serves as an index of the activity of large populations of neurons acting in synchrony and is an important measure of seizure activity in TSC. In addition, EEG signals, commonly quantified as event-related poten tials or by spectral analyses can provide a window for detecting cortical circuitry defects or abnormal functional connections in the human brain. Human EEG measures models 53, 78, 79 have been recapitulated in TSC mouse potentially serving as important tools for reverse trans lational studies. Functional and structural MRI can also serve as biomarkers to assess connectivity in the human brain. Prospective biomarker studies are ongoing in TSC using MRI and EEG (NCT01767779, NCT01780441). However, there remains a clear unmet need for improvement of existing biomarkers and for development of novel clinical biomarkers in multiple aspects of TSC. The field lacks sufficient biomarkers of disease burden and ac tivity, including dynamic measures of disease state (e.g., beyond static imaging of tumors). For example, a current limitation is our ability to assess lung involvement and disease progression by LAM in TSC. New tools are also required to better assess the clinical response to rapalogs and other targeted therapeutics, including biomarkers to measure target engagement, PD response, and to provide precision in assessing the clinical response to treatment. Improved measures of neural circuit function and func tional connectivity, e.g., would have broad utility for Short-term goals:
1. Facilitate biomarker discovery projects by supporting:
• longitudinal collection of biospecimens for aforementioned Bio/Data repository • the genotyping of patients or collection of samples in ancillary clinical studies • unbiased screening of biospecimen samples and tissues • additional data mining efforts in ongoing clinical studies 2. Convene a TSC biomarkers workshop
• take advantage of biomarker expertise in related neurodevelopmental or cancer/mechanistic target of rapamycin (mTOR) disorders
3. Develop strategies to assess signaling biology, target engagement, physiology, pathology across the domains of TSC, and in accessible tissue compartments; examples include research aimed to:
• develop more sensitive (e.g., novel positron emission tomography radiotracers) and/or non-invasive, accessible measures (e.g., skin im aging, electroencephalograph [EEG]) of TSC pathology including tools for early detection and screening • develop dynamic measures for functional assessment of TSC manifestations (beyond anatomic measures of pathology) and response to interventions • develop proximate readouts of target engagement and pharmacodynamics • better understand the pharmacodynamics of rapalogs • define excellent vs poor responders, extremes of phenotypes, and other aspects of clinical heterogeneity for patient stratification in clinical trials • develop measures that can be implemented across multiple sites and repeated over the life span 4. For neurological manifestations of TSC, develop and validate biological, molecular, neurophysiological (e.g., EEG), and imaging markers in conjunction with behavioral outcomes
• develop "next-generation" imaging tools to measure circuit function in the TSC patient population; e.g., motion insensitive, faster scans • conduct longitudinal studies to assess neurodevelopmental trajectories diagnosis, prognosis, and prediction in TAND and for use as PD biomarkers in clinical trials. Given the clinical heterogeneity in individuals with TSC, the development of risk stratification tools as predictive biomarkers of prognosis and clinical phenotype remains a high priority and one that will be required for prevention trials. Examples include the early characterization of slowly vs rapidly progressing tumors and markers that accurately predict those at high risk of developing epilepsy, autism spectrum disorder or other features of TAND, renal cell carcinoma, and clinically significant LAM. Improved ability to differentiate and predict excellent and poor responders to rapalogs would aid in patient selection for trials, help stratify TSC patients for personalized dosing, and ultimately facilitate more efficient trial design.
The workshop participants identified a number of strategies to facilitate biomarker discovery and develop ment in TSC ( Table 5 ), recognizing that such advances would provide synergy to other priority areas in TSC. There is also a need to develop translational biomarkers for preclinical models and human studies, incorporate bio specimen collection in clinical trials, and promote the translation of biomarkers into clinical practice. Appendix 4 (Supplementary Data) lists some of the current funding programs that potentially could support biomarker devel opment in TSC.
Priority Area V: Facilitating therapeutics and clinical trials research
Despite tremendous progress in treating the tumors in TSC, a number of crucial gaps remain especially for treating the neuropsychiatric manifestations of TSC. For example, there is a need to develop more sensitive and reliable end points in clinical trials of TAND, and to incorporate bio markers in the design of clinical trials. In addition, the identification of novel therapeutics beyond the rapalogs would potentially benefit all manifestations of TSC. To facilitate TSC therapeutics and clinical trials research, several short-term and long-term recommendations were developed (Table 6 ). Since 2011, there is an ongoing TSC Clinical Research Consortium funded by the NIH focusing on epilepsy and neuropsychiatric aspects of TSC. This Clinical Research Consortium has launched several studies in epilepsy and TAND in collaboration with the TS Alliance. Recommendations that can be adapted in the short term include significantly broadening the already existing Clin ical Research Consortium in terms of the number of participating sites and areas of research. The efforts of the Clinical Research Consortium can be used to expand clinical research into non-neurological manifestations of TSC (Table 6 ). To guide these expanded efforts, the steering committee should be broadened to include consultants with links to preclinical pharmaceutical and biotech com panies. These consultants will provide valuable input such as drug development pipeline information and patientperceived needs. In future clinical research, efforts should be made to recognize and include broader aspects of TSC and to gather more exploratory disease end points.
Longer term recommendations include development of methods to capture the effects of clinical interventions, including therapeutic and behavioral interventions. The 3. Before launching pivotal trials, conduct exploratory clinical studies to understand and determine optimal:
• dosing, timing, and duration of intervention (in conjunction with pharmacokinetic [PK]/pharmacodynamics [PD] measures) for a given manifestation of TSC • patient population; e.g., age, mutation type, stratifying excellent vs poor responders • biomarkers and clinical end points for trials 4 . In addition to treatment trials, there is an urgent need to develop:
• biomarkers and surrogate markers that target most of the patients and are validated by PD response and treatment outcome • more sensitive behavioral and cognitive outcome measures for clinical trials in TAND • combination therapies; e.g., drug therapy combined with behavioral/cognitive interventions for TAND • preventative therapies; e.g., determine whether early treatment can prevent progression to later stages in TSC and lymphangioleiomyo matosis (LAM); prevention of epilepsy in TSC 5. Follow and/or optimize the outcomes of existing clinical interventions over the long term; e.g.,
• conduct further studies to optimize the use of rapalogs and other mechanistic target of rapamycin (mTOR) inhibitors in LAM and TSC; e.g., determine the lowest effective dose; safety and efficacy with long-term use TAND checklist is an example of a successful measure in this regard. An organized but easy to implement approach can accelerate improvements in patient care and be used to facilitate longer term effects that extend beyond financial barriers of funding cycles. Surrogate end points including biomarkers and efforts aimed at disease pre vention are critical to daily clinical care and research. Finally, long-term prevention trials will need a method for funding to find preventative therapies (Supplementary Data: Appendix 4).
Conclusions
The workshop summary reported here describe a research strategy aimed at addressing the numerous med ical and neuropsychologic burdens associated with TSC while deciphering the biology underlying phenotypic het erogeneity. It is important to restate the major advances in TSC therapeutics that have occurred in the past ten years, including use of rapalogs for multiple aspects of TSC and use of vigabatrin for treatment of TSC infantile spasms. In spite of these advances, the TSC disease burden remains large. However, when the causes of interindividual variability are understood, individualized prognoses, surveillance, and treatments can be developed based on biomarkers that measure one's risk for each of the various manifestations. As new ways of treating each manifestation are developed through research on the different aspects of TSC, treatments can be personalized to maximize the riskebenefit ratio for each individual. We are not there yetdbut here we propose a research strategy designed to improve our understanding and treatment of TSC.
An important outcome of the workshop was the identi fication of key gaps and needs that cross all aspects of the disease, including better systems to acquire, annotate, and distribute biospecimens, improvement in animal models, development of better systems for standardized preclinical studies, and a broader clinical trials network including nonneurological manifestations of TSC. Focused workshops addressing a biospecimen repository and a preclinical trial consortium were held in October 2015.
To turn these research goals into accomplishments will require coordinated efforts of basic scientists, clinical researchers, academic centers, and industry partners. By reducing the barriers between institutions and disci plines, enhancing communication and collaboration, and promoting multi-site preclinical and clinical trials, the TSC research community is likely to build on the tremendous progress that has been achieved since the 2002 workshop. Such a collective effort is required to improve the lives of individuals and families affected with TSC.
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